OGN
$6.03-0.24 (-3.83%)
Organon & Co.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The co...
Recent News
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?
Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals.
3 Value Stocks We Approach with Caution
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
1 Stock Under $10 to Own for Decades and 2 That Underwhelm
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be careful as many have risky business models.
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know
Organon (OGN) closed at $6.23 in the latest trading session, marking a -2.5% move from the prior day.
A Look At Organon (OGN) Valuation After Recent Share Price Weakness
Organon (OGN) continues to attract attention after a challenging stretch, with the share price showing negative returns over the past year and past 3 months, prompting investors to reassess what the current valuation implies. See our latest analysis for Organon. The recent share price slide, including a 14.21% 30 day share price return and a 59.02% 1 year total shareholder return, points to fading momentum as investors reassess Organon’s risks and potential in light of its current US$6.34...